CAPRICOR THERAPEUTICS INC. - COMMON STOCK

Capricor Therapeutics Announces Initiation of Rolling Submission of Biologics License Application (BLA) with U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy

09 Oct 2024 09:15:00 By Nasdaq GlobeNewswire

NetDania - New 12 months High: CAPRICOR THERAPEUTICS INC. - COMMON STOCK

04 Oct 2024 09:47:23 By NetDania Notify

Capricor Therapeutics to Present Long-Term Data from HOPE-2 Open Label Extension Study at 2024 World Muscle Society Congress

04 Oct 2024 09:15:00 By Nasdaq GlobeNewswire

NetDania - New 12 months High: CAPRICOR THERAPEUTICS INC. - COMMON STOCK

01 Oct 2024 09:48:05 By NetDania Notify

NetDania - New 12 months High: CAPRICOR THERAPEUTICS INC. - COMMON STOCK

30 Sep 2024 11:30:56 By NetDania Notify

NetDania - New 12 months High: CAPRICOR THERAPEUTICS INC. - COMMON STOCK

25 Sep 2024 09:45:14 By NetDania Notify

NetDania - New 12 months High: CAPRICOR THERAPEUTICS INC. - COMMON STOCK

24 Sep 2024 09:45:18 By NetDania Notify

Capricor Therapeutics Announces Intent to File Biologics License Application for Full Approval of Deramiocel for the Treatment of Duchenne Muscular Dystrophy Cardiomyopathy

24 Sep 2024 08:00:01 By Nasdaq GlobeNewswire

Capricor Therapeutics to Provide Duchenne Muscular Dystrophy Program Update on September 24, 2024

23 Sep 2024 09:25:00 By Nasdaq GlobeNewswire

Capricor Therapeutics Signs Binding Term Sheet with Nippon Shinyaku for European Expansion and Commercialization of Deramiocel for the Treatment of Duchenne Muscular Dystrophy

17 Sep 2024 09:15:00 By Nasdaq GlobeNewswire

Capricor Therapeutics to Present at Upcoming Investor and Scientific Conferences

06 Sep 2024 08:30:00 By Nasdaq GlobeNewswire

Capricor Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

07 Aug 2024 16:05:01 By Nasdaq GlobeNewswire

Capricor Therapeutics to Present Second Quarter 2024 Financial Results and Recent Corporate Update on August 7

31 Jul 2024 09:00:00 By Nasdaq GlobeNewswire

Capricor Therapeutics Set to Join Russell 2000® and Russell 3000® Indexes

01 Jul 2024 09:00:00 By Nasdaq GlobeNewswire

Capricor Therapeutics Announces Long-Term Benefit of Deramiocel (CAP-1002) in Both Skeletal Muscle and Cardiac Function in the HOPE-2 OLE Study in Duchenne Muscular Dystrophy

28 Jun 2024 09:00:00 By Nasdaq GlobeNewswire

CORRECTION: Capricor Therapeutics

25 Jun 2024 10:30:57 By Nasdaq GlobeNewswire

Capricor Therapeutics Announces for the Treatment of Duchenne Muscular Dystrophy

25 Jun 2024 08:30:00 By Nasdaq GlobeNewswire

Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy with an Aim to Expedite BLA Pathway

11 Jun 2024 09:25:00 By Nasdaq GlobeNewswire

Capricor Therapeutics Announces Positive 3-Year Efficacy Results from HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy

04 Jun 2024 09:00:00 By Nasdaq GlobeNewswire

Capricor Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

13 May 2024 16:05:00 By Nasdaq GlobeNewswire